Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (Nasdaq: CLDI) is a clinical-stage biotechnology company developing cell-based cancer immunotherapy platforms, with programs spanning oncolytic virus delivery and allogeneic stem cell carriers. The company completed its business combination with FLAG Capital Acquisition Corp, a blank-check vehicle sponsored by FLAG Capital Management that conducted its IPO in 2021. The de-SPAC merger closed in September 2023, bringing Calidi to public markets in the biotechnology and oncology sector. On May 14, 2026, the company filed an 8-K current report with the SEC under accession number 0001493152-26-023094. Investors seeking full filing histories, sponsor backgrounds, and deal-level analytics on CLDI and thousands of other SPAC transactions can sign up for complete data access at SpacDesk.